Advocates call on Facebook to control vaccine misinformation; Democratic lawmakers to investigate government’s role in developing remdesivir; Pfizer CEO criticizes Trump drug price orders.
A number of pharma companies are pausing ads on the social network this month, either in solidarity with #StopHateForProfit’s July boycott or due to brand safety concerns.
The social giant says information collected will be stored securely, with controls on advertising.
Facebook Health’s Danielle Salowski and Merck’s Nancy Nolan shared best practices for Instagram at Digital Pharma East in Philadelphia.
For many online health communities, the Facebook-Cambridge Analytica scandal didn’t have a significant impact, and members still see the social network as an invaluable resource.
Despite some other positive indicators, Twitter’s share price fell 14% as the platform revealed a dip in its monthly active users in its second quarter results, compared to the previous quarter.
Facebook sought to blame GDPR as it revealed its daily active users in Europe declined for the first time in nine years and it disappointed investors with lower-than-expected growth.
Novocure and Glue Advertising put on a Facebook Live event promoting the cancer treatment Optune in March.
A WEGO Health white paper examined how the change could affect patient influencers.
Facebook’s decision to reprioritise its news feed to favour “social interactions” over other forms of content may please its users but will be challenging for brands.
